A dedicated bioimaging function at GSK has shown how integrated microscopy and analytics can deliver quantitative evidence ...

"Sanofi buys hep B vaccine maker for $2.2bn" was originally created and published by Pharmaceutical Technology, a GlobalData ...

Exdensur is the first biologic approved with twice-yearly dosing for severe eosinophilic asthma * Phase 3 trials showed significant reductions in asthma exacerbations with //Exdensur * The treatment ...

Samsung Biologics has agreed to acquire GlaxoSmithKline’s Human Genome Sciences and its two pharmaceutical manufacturing ...

Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making ...

Samsung Biologics said on the 22nd that it signed a deal with global drugmaker GSK plc to acquire the biopharmaceutical manufacturing facility of Human Genome Sciences (HGS) located in Rockville, ...

The Trump administration on Friday announced deals with nine drugmakers aimed at lowering pharmaceutical prices, bringing its total number of drug-pricing agreements to 14.

GSK’s fair value estimate has increased from £18.07 to £18.27, indicating a minor but notable shift in analysts’ outlook for the stock. This upward revision reflects a blend of optimism and caution as ...

GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. But that dream appeared to die this morning as the pharma closed the last programs related to this ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal antibody that targets interleukin-5, as an add-on ...